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A B S T R A C T   
The extracellular matrix (ECM) creates a multifaceted system for the interaction of diverse structural proteins, 
matricellular molecules, proteoglycans, hyaluronan, and various glycoproteins that collaborate and bind with 
each other to produce a bioactive polymer. Alterations in the composition and configuration of ECM elements 
influence the cellular phenotype, thus participating in the pathogenesis of several human disorders. Recent 
studies indicate the crucial roles of non-coding RNAs in the modulation of ECM. Several miRNAs such as miR-21, 
miR-26, miR-19, miR-140, miR-29, miR-30, miR-133 have been dysregulated in disorders that are associated 
with disruption or breakdown of the ECM. Moreover, expression of MALAT1, PVT1, SRA1, n379519, RMRP, PFL, 
TUG1, TM1P3, FAS-AS1, PART1, XIST, and expression of other lncRNAs is altered in disorders associated with 
the modification of ECM components. In the current review, we discuss the role of lncRNAs and miRNAs in the 
modification of ECM and their relevance with the pathophysiology of human disorders such as cardiac/ lung 
fibrosis, cardiomyopathy, heart failure, asthma, osteoarthritis, and cancers.   
1. Introduction 
The extracellular matrix (ECM) constitutes a multifaceted network of 
diverse structural proteins, matricellular molecules, proteoglycans, 
hyaluronan, and various glycoproteins that cooperate and link with each 
other to produce a bioactive polymer. This polymer regulates the me-
chanical features of tissues and the behavior of the existing cells. The 
final configuration of the ECM is defined by several parameters that 
regulate the production and turnover of each ECM element. Alterations 
in the composition and configuration of ECM constituents influence the 
cellular phenotype [1]. Non-coding RNAs (ncRNAs) are regarded as a 
novel regulatory system for modulation of the conformation of the ECM 
and therefore the phenotype of the cells that are located in this envi-
ronment [1]. These transcripts comprise the vast majority of tran-
scriptome of the mammalian genome, since although 80 % of 
mammalian genome is actively transcribed, only 2 % produce coding 
RNAs [2]. The association between the complexity of an organism and 
the plethora of ncRNAs [3], further support the importance of these 
transcripts in the developmental processes. They are principally classi-
fied into two classes according to their length. Those with sizes larger 
than 200 nucleotides are named as long non-coding RNAs (lncRNAs), 
while others constitute the small non-coding RNAs. The latter include 
microRNAs (miRNAs) and several other transcripts such as small inter-
fering RNAs and piwi-interacting RNAs [4]. LncRNAs have crucial roles 
in epigenetic regulation of chromatin arrangement through recruitment 
of epigenetic factors, promoter-specific control of gene expression, 
modulation of stability of transcripts, X-chromosome inactivation, and 
imprinting [4]. In addition, lncRNAs can function as structural co-
ordinators to partake in the establishment of subcellular organelles [5]. 
Other ncRNAs such as miRNAs participate in other layers of gene 
expression regulation. miRNAs exert their regulatory role through 
pairing with the transcripts of protein-coding genes to repress their 
expression at the post-transcriptional level [6]. In the current review, we 
discuss the role of lncRNAs and miRNAs in the modification of ECM and 
their relevance with the pathophysiology of human disorders such as 
cardiac/ lung fibrosis, cardiomyopathy, heart failure, asthma, 
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osteoarthritis and cancers. 
1.1. miRNAs and ECM 
These small non-coding RNAs are around 22 nucleotides in length 
and are produced through a multi-stage process. With the aid of RNA 
polymerase II, primary miRNAs are produced. RNA polymerase III is also 
involved in the transcription of some miRNAs, particularly miRNAs 
having upstream Alu sequences [7]. Subsequently, two cleavage events 
generate mature miRNAs from primary miRNAs. The first cleavage step 
is accomplished in the nucleus with the cooperation of Drosha and its 
cofactor DGCR8, while the second step is completed in the cytoplasm 
with the aid of another RNAse III enzyme termed Dicer. The resultant 
mature miRNAs amass into the RNA-induced silencing complex (RISC) 
[8]. 
1.2. miRNAs in the cardiac tissue 
Cardiac fibrosis has been associated with dysregulation of several 
miRNAs, including miR-34a and miR-93. These two miRNAs inhibit the 
expression of c-Ski, a protein that is significantly reduced in cardiac 
fibrosis, and the TGF-β1-induced animal model of cardiac fibroblasts. 
Functional studies showed the role of the miR-34a/miR-93-c-Ski axis in 
the regulation of TGF-β1- and isoproterenol-stimulated cardiac fibrosis. 
The underlying mechanism of this process has been the enhancement of 
fibroblasts proliferation and ECM alterations [9]. Other studies have 
demonstrated the role of miR-21, miR-26, miR-29, miR-30, and 
miR-133a in the induction of ECM fibrosis [10]. However, circulating 
levels of these miRNAs are not significantly different between patients 
with new-onset and chronic dilated cardiomyopathy, or between pa-
tients with and without fibrosis. Expression of miR-26 is correlated with 
ECM fibrosis. Moreover, peripheral expression of these miRNAs is 
correlated with several serum indicators of collagen metabolism, and 
expression miR-133a correlates with all aspects of ECM metabolism, 
namely collagen production, fibrosis regulating parameters, and matrix 
metalloproteinases (MMPs) and the related tissue inhibitors (TIMPs) 
[11]. 
1.3. miRNAs in the pathogenesis of intervertebral disc degeneration (IDD) 
ECM-associated miRNAs have also been implicated in the patho-
genesis of intervertebral disc degeneration (IDD). Wang et al. have 
shown differential expression of 29 miRNAs between nucleus pulposus 
(NP) samples obtained from IDD patients versus healthy subjects. 
Notably, expression of miR-21 was higher in degenerated NP samples in 
correlation with the amplitude of disc degeneration. This miRNA sup-
presses autophagy and enhances the expression of MMP-3 and MMP-9, 
resulting in the induction of Col II and aggrecan degradation. These 
effects were mediated through the PTEN/Akt/mTOR signaling pathway 
[12]. Liu et al. have assessed the expression of miR-7 in degenerative NP 
tissues and in IL-1β-induced NP cells. They have reported the 
up-regulation of miR-7 in human degenerative NP tissues and in IL-1β 
induced NP cells versus normal control samples. They have also reported 
GDF5 as a target of this miRNA. Up-regulation of miR-7 has increased 
the IL-1β-induced ECM degeneration, while its suppression has blocked 
NP cell harmful catabolic alterations in reaction to IL-1β. miR-7 partic-
ipates in the impairment of ECM in intervertebral discs via modulating 
GDF5 [13]. 
Fig. 1. IL-1β is increased in patients with osteoarthritis (OA). This cytokine increases reactive oxygen species (ROS) levels, activates HDAC3, and promotes nuclear 
transport of P65/P50 to enhance expression of MMP13 and ADAMTS-5 [17]. Moreover, IL-1β activates C-FOS and C-JUN and suppresses miR-30-a. This miRNA has a 
role in the suppression of ADAMTS-5 [18]. Another down-regulated miRNA in OA is miR-137. This miRNA has been shown to inhibit ADAMTS-5 expression [16]. 
Collectively, over-expression of MMP13 and ADAMTS-5 degrades ECM and participates in the pathogenesis of OA. 
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Table 1 
List and function of ECM-related miRNAs in human/ animal disorders (NP: nucleus pulposus).  









Cardiac Fibrosis (CF) miR-34a, miR- 
93 
SD rat – c-Ski, TGF-β1 – miR-34a/miR-93 could affect TGF-β1- 
induced fibroblasts proliferation and 
ECM deposition through c-Ski. 
[9] 
CF miR-154 12 pairs of cardiomyopathy 
and normal samples 
HCF, CFs GSK-3β, α-SMA Wnt/β-catenin miR-154 could inhibit GSK-3β 
expression by activating the Wnt/ 
β-catenin pathway, which promotes 
myocardial fibrosis. 
[24] 
CF miR-433 male C57BL/6 mice 
/Human; 4 pairs of cardiac 
fibrosis and normal heart 
tissues  
AZIN1, JNK1 TGF-β/Smad3, 
ERK, p38 
Downregulation of miR-433 could 
reduce cardiac fibroblast proliferation 
and myofibroblast differentiation in 
vivo and in vitro by targeting AZIN1 
and JNK1. 
[25] 
CF miR-26a-5p SD rat 293 T ULK1 – miR-26a-5p could regulate the 
autophagic pathway in cardiac 
fibroblasts. 
[26] 
CF miR-125b C57BL/6 J mice/Human; 6 
pairs of failing human hearts 
and normal hearts 
HCFs TGF-β, apelin p53 miR-125b could affect the induction of 
cardiac fibrosis and act as a potent 
repressor of multiple anti-fibrotic 
mechanisms. 
[27] 
CF miR-495 – CFs NOD1 NF-kB, TGF- 
β1/Smad 
miR-495 could reduce ECM 
accumulation of cardiac fibroblasts 













MMPs/TIMPs miR-26 could weakly correlate with 
ECM fibrosis. miR-26 and miR-133a 
could independently associate with 
ECM fibrosis. miR-26 and miR-133a 
could independently associate with 
fibrosis as well as correlated with the 
quantity of fibrosis. 
[11] 
Heart Failure (HF) miR-19a-3p/ 
19b-3p 
20 pairs of HF and normal 
patients 





Overexpression of miR-19a-3p/19b-3p 
could inhibit epithelial-mesenchymal 
transition (EMT) and extracellular 
matrix (ECM) production and invasion 
of HCF by targeting TGF-βR II. 
[28] 
Lung Fibrosis miR-140 C57BL/6 mice L-929, HEK- 
293 T 
Fn TGF-β 1/ 
Smad3 
Downregulation of miR-140 could 
increase the risk of radiation-induced 
lung fibrosis through reprogramming 
fibroblasts and macrophages. 
[29] 
Lung Fibrosis miR-1224-5p C57BL/6 mice NIH/3T3, 
MRC-5 
BECN1, TGF- PDGFR miR-1224-5p could mediate 
mitochondrial damage to affect silica- 
induced pulmonary fibrosis by 
targeting BECN1. 
[30] 
Lung Fibrosis miR-21 C57BL/6 mice IMR-90 TGFβ1 pRK5/ 
SMAD2/3/4 
miR-21 could increase effects on BLM- 
induced lung fibrosis and TGFβ1- 
induced ECM in IMR-90 cells. 
[31] 
Lung Fibrosis miR-497 SD rat RLE-6TN, 
HEK293 
TGFβ1 EIF3A miR-497 could inhibit TGFβ1-induced 
EMT, primary pulmonary fibroblast 
proliferation, and ECM protein 
expression. 
[32] 
Lung Fibrosis miR-29 – IMR-90 TGFβ1, COL1A1 Wnt/β-catenin miR-29 could mediate TGFβ1-induced 
ECM synthesis through activation of 
the Wnt/β-catenin pathway inhuman 
pulmonary fibroblasts. 
[33] 
Lung Fibrosis miR-29b – NIH-3T3, 
MRC-5, 
Raw264.7 
TIMP-1 – Overexpression of miR-29b could 
reduce the expression of ECM 
components in pulmonary fibrosis. 
[34] 
Asthma miR-143-3p 9 pairs of asthma and 
healthy patients 
ASMCs TGF-β1, CDK4, 
Cyclin D1 
NFATc1 Overexpression of miR-143-3p could 
decrease asthma airway remodeling by 
suppressing proliferation and ECM 
protein deposition in TGF-β1-mediated 
ASMCs via the negative regulation of 
NFATc1 signaling. 
[35] 
Asthma miR-204-5p 9 pairs of primary asthmatic 
subjects and non-asthmatic 
subjects 
HASMCs TGF-β1 TGF/Smad3 miR-204-5p could reduce ECM 
production of airway smooth muscle 
cells by regulating Six1 in asthma. 
[36] 
Asthma miR-223 SD rat ASMCs IGF-1R, TGF-β1 IGF-1R/PI3K- 
Akt 
Overexpression of miR-223 could 
decrease the expression of proteins 
involved in the extracellular matrix, 
such as α-SMA (ACTA2), and type I and 
III collagens. 
[14] 
Keloid miR-203 10 pairs of Keloid tissue 
specimens and normal skin 
tissues 
– EGR1, FGF2 – miR-203 overexpression in vitro led to 
a significant decrease in ECM 
production in keloid fibroblasts. 
[37] 
(continued on next page) 
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Table 1 (continued ) 















Smad2 AKT, TGF-β miR-205-5p could regulate ECM 




miR-21 BALB/c nude mice /Human; 
9 pairs of HS tissue and 






miR-21 could affect hypertrophic scar 
formation in TGF- β1 /miR-21/Smad7 
signaling. 
[39] 
Skin Fibrosis miR-9-5p C57BL/6 mice HDFs TGFBR2 TGF-β miR-9-5p overexpression could 





miR-338-5p 5 pairs of cases complicated 
with sIUGR and normal 
patients 
293 T, HTR- 
8/SVneo 
EFEMP1 AKT miR-338-5p could affect growth and 
invasion of trophoblast cells in 
selective intrauterine growth 
restriction by targeting epidermal 
growth factor-containing fibulin-like 
extracellular matrix protein 1. 
[41] 
– miR-29 TSP2 KO mice Primary 
dermal 
fibroblast 
TSP2 – Regulating of miR-29 by TSP2 could 
contribute to ECM production. 
[42] 





TGF-β Overexpression of miR-21a-5p could 
affect the expression of ECM mediators 
in uterine leiomyoma. 
[43] 





ERK1/2 miR-126-3p could promote matrix- 
dependent perivascular cell 
attachment, migration, and 
intercellular interaction. 
[44] 
Obesity miR-181d C57BL/6 J mice, BMP4 
transgenic mice /Human; 30 
Pairs of subcutaneous and 




Adamts1 FAK–ERK1/2 miR-181d could promote adipocyte 
lineage commitment by regulating 
Adamts1-ECM-FAK–ERK axis. 
[25] 
– miR-29c SD rat RAOSMCs Col3A1, 
Col4A5, ELN, 
MMP2 
– miR-29c could mediate the inhibitory 
effect of glucocorticoids on ECM gene 
expression. 
[45] 
Glaucoma miR-483-3p – HTMCs, 
293 T 
Smad4 TGF/Smad miR-483-3p could reduce ECM 
production by targeting Smad4 in 
human trabecular meshwork cells. 
[46] 
– miR-29b C57 mice – TGF-β TGF-β1/ 
Smad/CTGF 
Overexpression of miR-29b could 
promote wound healing, alleviates 
pathomorphology change in scar 
tissues, and reduces ECM production by 
inhibiting TGF-β/Smad/CTGF 
signaling pathway in the scalded model 
of mice. 
[47] 
Osteoarthritis (OA) miR-137 25 OA cartilage tissues and 
15 normal control cartilage 
tissues 
– ADAMTS-5, IL- 
1β 
– Overexpression of miR-137 suppressed 
cell growth, ECM degradation through 
regulating ADAMTS-5 in chondrocytes. 
[16] 
OA miR-449a 20 OA cartilage samples and 
10 normal cartilage samples 
SW1353 GDF5 – miR-449a upregulation could promote 
chondrocyte ECM degradation in OA. 
[48] 
OA miR 221/483- 
5p 
8 OA cartilage samples and 5 
normal cartilage samples 
– RAF1, MAPK3, 
MAPK1, ELK1 
MAPK, p27 miR-221/483-5p could modulate 
proliferation and matrix synthesis in 
chondrocytes. 
[49] 
OA miR-30a Sd rat/Human; 11 OA 
patients and 7 healthy 
donors 
– Sox9 – miR-30a could promote ECM 
degradation in articular cartilage via 
the downregulation of Sox9. 
[50] 
OA miR-19b-3p 12 OA articular cartilage 
samples and 6 Normal none- 
OA cartilages 
ATDC5 IL‑1β, GRK6 GRK6-NF-kB Overexpression of miR-19b-3p could 
decrease IL-1β induced ECM 
degradation and inflammatory injury 
in chondrocytes by targeting GRK6. 
[51] 
OA miR-140 SD rat/Human; 10 OA 
cartilage samples and 7 
normal cartilage samples 
– MMP-13, 
ADAMTS-5 
– miR-140 could reduce the OA 
progression by modulating ECM 
homeostasis in rats. 
[52] 
OA miR-634 15 OA cartilage samples and 
6 normal cartilage samples 
– PIK3R1 PI3K/Akt/S6, 
PI3K/Akt/ 
mTOR/S6 
Overexpression of miR-634 could 
suppress survival and matrix synthesis 
of human OA chondrocytes by 
targeting PIK3R1. 
[53] 
OA miR-29a, miR- 
140 
sucking mice – IL-1β, MMP13, 
TIMP1 
– miR-29a and miR-140 synergistically 
could suppress cell-matrix signaling by 
regulating the TIMP1and MMP13 
protein level and the release of type II 
collagen. 
[54] 
OA miR-107 45 pairs of OA cartilage 
tissues and non-OA patient 
tissues 
C28/I2 PTEN – miR-107 could induce chondrocyte 
growth and ameliorated cartilage 
degradation by targeting PTEN in OA. 
[55] 
OA miR-497-5p 12 OA patients and 10 
normal human cartilages 
– IL-1β Wnt/β-catenin miR-497-5p could reduce IL-1β- 
induced cartilage matrix degradation 
in chondrocytes via the Wnt/β-catenin 
pathway. 
[56] 
(continued on next page) 
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Table 1 (continued ) 









OA miR-140 9 OA cartilage samples – MMP-13, IL-1β, 
ADAMTS-5 
ER/miR-140 miR-140 could affect IL-1β-induced 
ECM degradation in human 
chondrocytes. 
[57] 
OA miR-30a 76 pairs of OA tissues and 
adjusted normal tissues 
– ADAMTS-5 IL-1β/AP-1/ 
ADAMTS-5 
miR-30a could act as a pivotal 
regulator of cartilage homeostasis in 
OA. 
[58] 
OA miR-26a C57BL/6 mice PECs Cd200, Col10a1 – Downregulation of miR-26a expression 
could contribute to ECM changes in 
cartilage diseases. 
[59] 
OA miR-101 SD rat – Sox9, MMPs, 
TIMPs, TGFs, 
VEGF 
– Downregulation of miR-101 could 
prevent cartilage degradation by 
regulating ECM related genes in a rat 
model of osteoarthritis. 
[60] 
OA miR-221-3p 86 OA cartilage samples and 
59 normal cartilage samples 
SW1353, 
C28I2 
IL-1β, SDF1 SDF1/CXCR4 Downregulation of miR-221-3p could 
contribute to IL-1β-induced cartilage 
degradation by directly targeting the 







14 dSSc tissues and 12 
normal healthy tissues 
– a-SMA TGF-b miR-21 and miR-29a could modulate 
the expression of collagen in dermal 





miR-206 – MCs – ERK Overexpression of miR-206 could 
decrease the proliferation of ECM cells 
and secretion and expression of ECM 
protein in DN. 
[63] 




Overexpression of miR-214 could 
decrease cell hypertrophy and 
expression of the matrix protein 
fibronectin in DN. 
[64] 
DN miR-146a C57BL/6 crossed with CBA/J 
mice 
HRECs IL-6, TNFα, IL1β NF/κB miR-146 upregulation could prevent 
structural and functional changes in the 
kidneys and retina of diabetic animals. 
[20] 
DN miR-206 – 293 T, HK-2 HIF-1α – miR-206 could reduce cell proliferation 
and ECM accumulation in DN by 
targeting HIF-1α. 
[19] 
DN miR-370 SD rat – CNPY1 – overexpression of miR-370 could 
promote mesangial cell proliferation 
and ECM accumulation by suppressing 
CNPY1 in a rat model of DN. 
[21] 
DN miR-26a Male C57BL/6 J mice/ 
Human; 11 DN patients 
– TGF-β, CTGF TGF-β/SMAD miR-26a could inhibit TGF-β/CTGF- 
induced ECM accumulation in diabetic 
nephropathy both in humans and in 
mice. 
[65] 
DN miR-382 male C57BL/6 mice – FoxO1 FoxO Downregulation of miR- 382 could 
inhibit ECM accumulation via FoxO1 in 
mice with diabetic nephropathy. 
[26] 





miR-146a overexpression could 
mediate fibrosis in the heart in diabetic 
condition. 
[66] 
– miR-590 – HUMSCs Smad7 TGF-β Overexpression of miR-590 could 
promote the proliferation of HUMSCs 
and induces ECM synthesis by targeting 
Smad7. 
[52] 
Liver Fibrosis miR-185 C57BL/6 mice/Human; 10 
liver fibrosis patients, 8 
healthy 




miR-185 could prevent liver 
fibrogenesis by inhibiting HSC 
activation via inhibition of RHEB and 
RICTOR. 
[22] 
Liver Fibrosis miR-19b-3p C57BL/6 mice HSCs, KCs SphK1 SphK1/CCL2/ 
CCR2 
miR-19b-3p could reduce CCR2- 
mediated liver fibrosis. 
[67] 
Liver Fibrosis miR-203 – HSC-T6 SMAD3, 
COL1A1, 
COL3A1, α‑SMA 
TGF‑β/Smad miR-203 could prevent the synthesis 
and deposition of ECM components, 
including COL1A1, COL3A1, and 
α-SMA in liver fibrosis. 
[23] 
Liver Fibrosis miR-30c, miR- 
193 
Mouse/Human; 72 liver 
fibrosis patients and 19 
matched healthy controls 
GRX TGF-β2, SNAIL1 TGF‑β miR-30c and miR-193 could affect ECM 
genes in liver fibrosis by TGF- 
β-dependent regulatory network. 
[68] 
Liver Fibrosis miR-200a SD rat HSC-T6 TGF-β1 SIRT1/Notch1 miR-200a could control hepatic stellate 
cell activation and fibrosis via SIRT1/ 
Notch1 signal pathway. 
[69] 
Liver Fibrosis miR-34a SD rat L-02, LX-2 SIRT1, α-SMA, 
TGF-β1 
SIRT1/p53 Activation of the miR-34a/sirt1/p53 
signaling pathway contributes to the 
progress of liver fibrosis via inducing 
apoptosis in hepatocytes but not in 
HSCs. 
[70] 
Liver Fibrosis miR-29a C57BL/6 J 6 mice LX-2 COL1A1 PDGFC [71] 
(continued on next page) 
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Table 1 (continued ) 









miR-29a could prevent the activation 
of human stellate cells and promote 
recovery from liver fibrosis in mice. 
– miR-34 – VSMCs, 
UVECs, 
HEK293 T 
AAT – miR-34 could affect vascular diseases 






miR-29b 6 human corneas iFECD COL1A1, 
COL4A1, 
LAMC1 
– Overexpression of miR-29b could 
decrease ECM protein production in 




miR-486-5p – NP, HEK293 FOXO1, MMP- 
3/13, ADAMTS- 
4, ADAMTS-5 
– miR-486-5p could inhibit ECM 
degradation in NP cells by directly 
targeting FOXO1. 
[74] 
IDD miR-21 65 IDD NP lumbar samples 
and 45 control lumbar NP 
tissue samples 
NPCs PTEN PTEN/Akt/ 
mTOR 
miR-21 could promote ECM 
degradation through inhibiting 
autophagy via the PTEN/Akt/mTOR 
signaling pathway in human 
degenerated NP cells. 
[12] 
IDD miR-145 24 IDD NP lumbar samples 
and 5 control lumbar NP 
tissue samples 
NPCs ADAM17 – miR-145 overexpression could 
decrease apoptosis and increases 
matrix synthesis in nucleus pulposus 
cells. 
[75] 
IDD miR-140-5p 16 NP lumbar samples HNPCs CREB1 NF-kB Overexpression of miR-140 could affect 
ECM degradation. 
[76] 
IDD miR-483-3p SD rat/Human; 24 cases of 
IDD tissues and 16 cases of 
spinal cord injury tissues as 
control. 




Wnt miR-483-3p could affect ECM 
remodeling in IDD by targeting GSK3B. 
[76] 
IDD miR-132 SD rat/Human; 27 IDD NP 
lumbar samples and 14 
control lumbar NP tissue 
samples 
NPCs GDF5, MMP13, 
ADAMTS4 
MAPK/ERK miR-132 upregulation could promote 
matrix degradation in intervertebral 
disc degeneration 
[77] 
IDD miR-34a 10 lumbar NP tissues from 
IDD patient and 4 lumbar NP 
from normal control patient 
HEK293, 
NPCs 
IL-1b, GDF5 – Downregulation of miR-34a could 
reduce IL-1b-induced ECM degradation 
in nucleus pulposus by increasing 
GDF5 expression 
[50] 
IDD miR-7 12 lumbar NP tissues from 
IDD patient and 8 lumbar NP 
from normal control patient 
HEK293, 
NPCs 
IL-1b, GDF5 MAPK Overexpression of miR-7 could increase 
the IL-1b-induced ECM degeneration. 
[13] 
IDD miR-494 20 IDD NP samples NPCs SOX9 NF/κB miR-494 could promote apoptosis and 
ECM degradation in degenerative 
human nucleus pulposus cells. 
[78] 
IDD miR-98 116 lumbar NP specimens 
and 102 normal healthy 
samples 
NPCs IL-6 IL-6/STAT3 Dysregulation of miR-98 could 
Contribute to ECM degradation by 
targeting the IL-6/STAT3 pathway in 
human IDD. 
[79] 
IDD miR-499a-5p 19 IDD NP lumbar samples 
and 5 control lumbar NP 
tissue samples 
NPCs SOX4, TNF-α – miR-499a-5p could decrease the 
apoptosis of human nucleus pulposus 
cells and degradation of their 
extracellular matrix by targeting SOX4. 
[80] 
IDD miR-30d 20 IDD NP lumbar samples 
and 10 control lumbar NP 
tissue samples 
NPCs SOX9 – Downregulation of miR-30d could 
reduce ECM degradation of 
degenerative human nucleus pulposus 
cells by upregulating SOX9. 
[81] 
IDD miR-155 C57 mice/Human; 10 IDD 
NP lumbar samples and 5 
control lumbar NP samples 
HEK 293, 
NPCs 
MMP-16 – Downregulation of miR-155 could lead 
to the dehydration and degeneration of 
discs. 
[82] 
– miR-29 C57BL/6 mice, SD rat HS895-SK MP2, FSTL1, 
TGFB3 
– miR-29 could decrease ECM expression 
and Fibroplasia in the Skin. 
[83] 
Psoriasis miR-4516 15 psoriasis cases HaCaT, 
NHEK 
FN1, ITGA9 FN1/ITGA9 Downregulation of miR-4516 in 
psoriatic skin could accelerate 
migration, resistance to apoptosis, and 
differentiation as seen in psoriasis 
lesional keratinocytes. 
[84] 
Aortic Aneurysm miR-29b – ASMCs PGE2 – miR-29b could affect the fibrotic ECM 
expression in the abdominal aortic 




20 pairs of glioma brain 




MT1-MMP – miR-150-5p and miR-133a could 
suppress glioma cell proliferation and 
migration by targeting membrane- 




miR-124 80 RA patients and 32 
control subjects 
– MMP-3 – Downregulation of miR-124 in RA 
patients could affect MMP-3 levels and 
extracellular matrix remodeling, which 
is associated with the age of RA onset. 
[87] 
miR-144 male miR-144 KO mice – Zeb1, LOX1 Zeb1/LOX1 [88] 
(continued on next page) 
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1.4. miRNAs in the pathogenesis of airway disorders 
Asthma has been associated with the remodeling of the airways by 
airway smooth muscle cells (ASMCs). miR-223 is among miRNAs whose 
up-regulation has resulted in the induction of a phenotypic shift in these 
cells leading to the down-regulation of proteins contributing in the ECM 
including α-SMA (ACTA2), and type I and III collagens. Insulin-like 
growth factor-1 receptor (IGF-1R) has been identified as the target of 
miR-223 which results in the phenotypic shift of ASMCs. Suppression of 
IGF-1R by miR-223 deceases AKT1 levels in ASMCs. Therefore, miR-223 
inhibits the fibrotic phenotypes of ASMCs through the PI3K/Akt axis and 
IGF-1R [14]. Expression of miR-181a is enhanced in TGF-β1-induced 
airway smooth muscle cells. This miRNA has been shown to suppress cell 
proliferation, migration, and over-production of ECM. Mechanistically, 
miR-181a participates in this process through targeting PTEN. Thus, the 
effects of TGF-β1 in the induction of airway smooth muscle cell prolif-
eration and airway remodeling are exerted through the miR-181a/ 
PTEN axis and the subsequent activation of the Akt/mTOR pathway 
[15]. 
1.5. miRNAs in the pathogenesis of osteoarthritis (OA) 
OA, as the most frequent degenerative disorder in the joints, is 
associated with the dysregulation of a number of miRNAs, including 
miR-137 whose expression in the chondrocytes is inhibited by IL-1β. The 
expression of miR-137 is decreased in OA patients compared with con-
trols [16]. Functional studies have verified the binding of miR-137 with 
the 3’ UTR of ADAMTS-5. Consistently, expression of ADAMTS-5 is 
higher in OA cases compared with controls. Up-regulation of miR-137 
inhibits cell growth, ECM destruction, and inflammatory reactions in 
chondrocytes [16]. 
Fig. 1 shows the contribution of some miRNAs in the degradation of 
ECM in the context of OA. 
1.6. miRNAs in the pathogenesis of diabetic nephropathy 
Several miRNAs are involved in the pathogenic events in ECM in the 
context of diabetic nephropathy. In vitro studies have shown the role of 
miR-206 in the suppression of cell proliferation and ECM buildup 
through targeting HIF-1α in glomerular mesangial cells exposed to high 
concentrations of glucose. Yet, they demonstrated down-regulation of 
this miRNA in these cells following such exposure [19]. Moreover, in 
vivo animal studies have verified the role of miR-146a in the regulation 
of the glucose-induced upsurge in inflammatory cytokines and ECM 
proteins and are implicated in both diabetic retinopathy and nephrop-
athy [20]. Experiments in model of diabetic nephropathy have shown 
over-expression of miR-370, fibronectin, type I and IV collagen, and 
plasminogen activator inhibitor-1 (PAI-1) while decrease in CNPY1 
levels. Further functional experiments have validated the role of 
miR-370 in the enhancement of mesangial cell proliferation and ECM 
accretion through the suppression of CNPY1 [21]. 
Table 1 (continued ) 











Downregulation of miR-144 could 
interrupt ECM remodeling after MI by 
targeting the Zeb/LOX pathway. 
Bone Fracture miR-214-5p 28 patients with a fracture 
and 6 healthy controls 
Mc3T3-e1 coL4A1, coL-II, 
coL-X 
– Downregulation of miR-214-5p could 
promote cell survival and ECM 
formation by targeting coL4A1 in 







HEK-293 T COL7A1 TGF- 
β/Smad3/4 
Downregulation of miR-29 in RDEB 
skin leads to an increase of pro-fibrotic 
extracellular matrix collagens. 
[90]  
Table 2 
Role of ECM-associated miRNAs in cancer.  
Disease microRNA Animal/human; numbers 
of clinical samples 







miR-200s 75 pairs of BC tissues and 
adjacent normal 
mammary tissues 
CAFs, NFs, GES Fli-1, TCF12 – miR-200 s could affect BC cell invasion 
through ECM remodeling. 
[92] 
BC miR-203 Robo1 mice/Human; 142 







Downregulation of miR-203 could regulate 
cell shape and matrix adhesion through 













Downregulation of miR-106a/b could affect 
BC stem-like cell properties via interaction 




miR-92a male BALB/C nude mice/ 
Human; 74 pairs of GC 





ECM1 – Downregulation of miR-92a could facilitate 
the effect of ECM1 which promotes gastric 
cancer cell metastasis in cell migration 
assays by facilitating the expression of 









47 pairs of NSCLC tumor 






– miR-17 and miR-20a could influence ECM 







50 pairs of CRC samples 
and adjacent tissues 
HCT116, NCM460, 
HEK293, SW-60 
MAGP2 Notch miR-200b-3p by targeting MAGP2 could be 
involved in CRC progression. 
[97]  
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1.7. miRNAs in the pathogenesis of liver fibrosis 
Liver fibrosis is another example of an ECM-associated disorder that 
is associated with the activity of a number of miRNAs. Assessment of the 
role of miR-185 liver fibrosis identified decreased plasma levels of miR- 
185 in hepatitis B virus-related liver fibrosis patients compared with 
healthy subjects [22]. Animal studies showed down-regulation of this 
miRNA in CCl4-induced fibrotic liver tissues and TGF-β1-activated he-
patic stellate cells, which was accompanied by up-regulation of RHEB 
and RICTOR. Mechanistically, miR-185 was shown to directly suppress 
the expression of these genes, thus preventing liver fibrosis [22]. 
miR-203 silencing has been shown to enhance proliferation of hepatic 
stellate cells, while its up-regulation has been shown to inhibit the 
proliferative aptitude of these cells. Besides, SMAD3 has been identified 
as a direct target of miR-203. miR-203 might inhibit the production and 
deposition of ECM constituents such as COL1A1, COL3A1 and α‑SMA, 
and suppress proliferation of hepatic stellate cells via a 
SMAD3-dependent route [23]. Table 1 shows the list of ECM-related 
miRNAs and their function in human/ animal disorders. 
1.8. ECM-associated miRNAs and cancer 
Anomalous ECM dynamic has been regarded as a prominent feature 
of cancer. Desmoplasia in the tumor tissues has been associated with 
high levels of deposition of ECM proteins, dysregulation of their struc-
tures and altered pattern of post-translational modifications [91]. 
Numerous studies have reported aberrant expression of miRNAs in as-
sociation with these abnormalities in ECM proteins (Table 2). 
Expression of ECM-associated miRNAs is associated with the survival 
of affected individuals. Most of these studies have been conducted on 
cancer patients. For example, up-regulation of microfibril-associated 
glycoprotein 2 in colorectal cancer clinical samples and cells has been 
shown to be associated with numerous clinicopathologic characteristics 
of patients, and its over-expression predicted poor survival of patients 
[97]. The expression of this glycoprotein has been shown to regulate at 
the post-transcriptional level by miR-200b-3p. Therefore, the low 
expression of this miRNA has been suggested as an indicator of poor 
survival of patients with colorectal cancer [97]. As another example, 
downregulation of miR-200 s in normal fibroblasts led to the induction 
of features of activated cancer-associated fibroblasts (CAFs) in breast 
cancer tissues, such as enhanced migration and invasion. Forced 
expression of this miRNA in CAFs restored the phenotype of normal fi-
broblasts in these cells. miR-200 s has been shown to control CAF acti-
vation through modulation of expression of Fli-1 and TCF12. This 
miRNA has an additional effect on the enhancement of expression of 
fibronectin and lysyl oxidase. Finally, over-expression of miRNA-200 s 
targets Fli-1 and TCF12 in activated normal fibroblasts, and in breast 
cancer, the stromal milieu is associated with poor survival of breast 
cancer patients [92]. Table 3 shows the results of studies that assessed 
the association between ECM-associated miRNAs and survival of 
affected individuals/ animals. 
1.9. LncRNAs and ECM 
LncRNAs have been shown to regulate the expression of several 
ECM-associated molecules, thus being implicated in the pathogenesis of 
ECM-related disorders. 
1.10. LncRNAs and glaucoma 
Induction of apoptosis in human trabecular meshwork cells (HTMCs) 
and extreme accumulation of ECM constituents contribute to the path-
ogenesis of open-angle glaucoma. Assessment of the role of lncRNAs in 
HTMCs under oxidative stress conditions revealed altered expression of 
several TGF-β-associated lncRNAs and mRNAs [98,99]. Further inves-
tigation found that the lncRNA lnc-TGFβ2-AS1 led to increased ECM 
construction through modulation of TGF-β2 in HTMCs [98]. In addition, 
lncRNA-RP11-820 has regulatory functions in ECM synthesis in HTMCs. 
Expression of this lncRNA has been increased under oxidative stress in 
these cells. Functionally, lncRNA-RP11-820 binds with miR-3178, thus 
regulating MYOD1 levels. MYOD1 can induce ECM genes in HTMCs in 
coordination with STAT3 [100]. 
1.11. LncRNAs in cardiac tissue remodeling 
In a mechanistic study, the lncRNA SRA1 was found to play a role in 
the stimulation of cardiac myofibroblasts [101]. The investigators 
showed up-regulation of SRA1 in an animal model of cardiac fibrosis and 
that SRA1 silenced suppressed cell proliferation, myofibroblast trans-
formation, and collagen synthesis of cardiac myofibroblasts. Mechanis-
tically, SRA1 was shown to target miR-148b in cardiac myofibroblasts 
[101]. MIAT has been shown to be involved in the induction of fibrosis 
in hypertrophic cardiomyopathy through suppression of expression of 
miR-29a. Both MIAT and miR-29a could predict the prognosis of pa-
tients with hypertrophic cardiomyopathy [102]. 
1.12. LncRNAs in diabetic nephropathy 
Expression of MALAT1 has been increased while miR-145 has been 
decreased in kidney tissues of db/db mice. Moreover, hyperglycemia has 
been shown to increase the level of MALAT1 yet reduced miR-145 levels 
in a normal proximal tubular cell line. MALAT1 and miR-145 control 
high glucose-induced EMT and fibrosis. Functionally, MALAT1 acts as a 
sponge for miR-145 to up-regulate expression of ZEB2, thus activating 
inducing EMT and fibrosis [103]. Besides, LINC00968 knock down has 
suppressed secretion of ECM proteins and mesangial cells proliferation 
through the EZH2/p21 axis [104]. 
1.13. LncRNAs and OA and osteochondropathy 
Wang et al. showed up-regulation of XIST in OA samples and artic-
ular chondrocytes extracted from OA tissues and IL‑1β-exposed cells. 
XIST silencing was found to inhibit the destruction of the ECM via 
sponging miR-1277-5p. Experiments in an animal model of OA 
confirmed the protective role of XIST silencing against ECM degradation 
[102]. In addition, overexpression of FOXD2-AS1 by targeting 
miR-27a-3p could induce ECM degradation in chondrocytes [105]. 
LncRNAs are also implicated in the pathogenesis of Kashin-Beck disease, 
which is a deformative, endemic osteochondropathy. Using a 
microarray-based approach, differential expression of approximately 
1000 lncRNAs was detected in KBD chondrocytes versus normal chon-
drocytes [106]. Co-expression and pathway analyses revealed that 34 
mRNAs and 55 co-expressed lncRNAs organize a network that regulates 
the ECM [106]. 
Table 3 
Association between ECM-associated miRNAs and survival of affected in-
dividuals/ animals (OS: overall survival).  
Sample number Kaplan-Meier analysis Ref 
10 liver fibrosis patients, 8 healthy 
persons 
Low expression of miR-185 was 
associated with poor OS rates. 
[22] 
50 pairs of colorectal cancer 
samples and adjacent tissues 
Low expression of miR-200b-3p was 
associated with better OS rates. 
[97] 
75 pairs of breast tumor tissues and 
adjacent normal mammary 
tissues 
Overexpression of miR-200 s was 
associated with poor OS rates. 
[92] 
Mouse/Human; 142 breast cancer 
tissue samples 
Low expression of miR-203 was 
associated with better OS rates. 
[93] 
Mouse/Human; 74 pairs of gastric 
cancer and adjacent normal 
specimens 
Low expression of miR-92a was 
associated with better OS rates. 
[95]  
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Table 4 
List and function of ECM-related lncRNAs in human/ animal disorders.  
Cancer type lncRNA Animal/human; Numbers 








Glaucoma TGFβ2-AS1 – HTMCs TGF-β2, SMAD2, 
SMAD3 
TGF-β The expression of 
ENST00000414452 (TGFβ2-AS1) 
was increased in HTMCs when 
treated with H2O2. TGFβ2-AS1 
via targeting TGF-β2 could 
promote ECM production in 
human trabecular meshwork 
cells. 
[98] 
Glaucoma RP11-820 – HTMCs miR-3178, 
MYOD1, STAT3, 
Coll-I, Fibronectin 
– RP11-820 via regulating miR- 
3178/MYOD1 axis could 
promote ECM production in 





SRA1 SD rats Cardiac 
myofibroblasts 
miR-148b – ββ by competitively binding miR- 
148b could promote the 
activation of cardiac 
myofibroblasts 
[101] 
CF n379519 SD rat Cardiac 
myofibroblasts 
miR-30, Coll-I/III – n379519 by targeting miR-30 
could promote cardiac fibrosis in 
post-infarct myocardium. 
[109] 
CF GAS5 Male C57BL/6 mice – PTEN, MMP-2, 
Coll-I, α-SMA 
– Overexpression of GAS5 via 
regulating the PTEN/MMP-2 
signal pathway could attenuate 
cardiac fibrosis in mice. 
[110] 




– Upregulation of RMRP by 
regulating miR‑613 could 
promote the activation of cardiac 
fibroblasts. 
[111] 





– PFL by targeting let-7d could 
contribute to cardiac fibrosis. 
[112] 
CF GAS5 C57BL/6 mice – PTEN, MMP-2, 
Coll-I, α-SMA 
– Overexpression of GAS5 via 
regulating the PTEN/MMP-2 
signal pathway could attenuate 
cardiac fibrosis in mice. 
[110] 






GAS5 by targeting miR-21 via the 
PTEN/MMP-2 signaling pathway 
could control cardiac fibroblast 
activation and fibrosis. 
[113] 
Osteoarthritis (OA) TUG1 Cartilage tissues from 
patients with OA (n = 15) 
and patients without OA 
(n = 15) 
Chondrocyte miR-195, MMP- 
13, Coll-II, 
Aggrecan 
– TUG1 via the miR-195/MMP-13 
axis could promote OA-induced 
degradation of chondrocyte 
ECM. 
[114] 
OA TM1P3 45 pairs of RF and adjacent 
normal control tissues 
Chondrocyte miR-22, ALK1, 
MMP13,SMAD1/ 
5 
TGF-β TM1P3 via the miR-22/MMP13/ 
TGF-β axis is involved in the 
degradation of chondrocyte 
ECM. 
[115] 
OA FAS-AS1 Cartilage tissues from 
patients with OA (n = 20) 
and patients without OA 
(n = 20) 
Chondrocyte MMP1/13, 
COL2A1 
– FAS-AS1 could promote the 
degradation of ECM of cartilage 
in OA. 
[116] 
OA PART1 Cartilage tissues from 
patients with OA (n = 35) 
and patients without OA 




– PART1 via regulating the miR- 
373-3p/SOX4 axis could 
modulate chondrocyte 
proliferation and ECM 
degradation in OA. 
[117] 
OA XIST Samples of cartilage 
collected from non-OA 




– XIST by targeting miR-1277-5p 
could promote ECM degradation 
in OA. 
[102] 
OA CIR Samples of cartilage 
collected from non-OA 
(n = 8) and OA (n = 30) 
Chondrocyte MMP-13, miR-27 – CIR by targeting miR-27b could 
promote chondrocyte ECM 
degradation in OA. 
[47] 
OA FOXD2-AS1 Samples of cartilage 
collected from non-OA 





– Overexpression of FOXD2-AS1 
by targeting miR-27a-3p could 
induce ECM degradation in 
chondrocytes. 
[105] 
OA MALAT1 Samples of cartilage 
collected from non-OA 





– MALAT1 by miR-145/ADAMTS5 
could adjust IL-1β-Induced 
chondrocytes viability and 
cartilage ECM degradation in 
Human OA. 
[118] 
OA MEG3 Mal SD rat Chondrocyte MMP-13, 
ADAMTS-5,  
MEG3 by targeting miR-93/ 
TGFBR2 Axis could inhibit the 
[117] 
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Table 4 (continued ) 
Cancer type lncRNA Animal/human; Numbers 










degradation of the ECM of 




CDKN2B-AS1 24 patients with DN and 20 




PI3/Akt Silencing of CDKN2B-AS1 via the 
miR-424-5p/HMGA2 axis could 
repress proliferation and ECM 
accumulation. 
[119] 




– Overexpression of NEAT1 by 
targeting miR-27b-3p and ZEB1 
could promote ECM 
accumulation and EMT in 
diabetic nephropathy. 
[120] 
DN NR_033515 Normal patient serum 
(n = 111) and DN patient 







– NR_033515 by targeting miR- 
743b-5p could promote 
proliferation and fibrogenesis in 
DN. 
[121] 
DN MALAT1 db/db mice HK-2, 293 T E-cadherin, 
α-SMA, ZEB2, 
miR-145 
– MALAT1 via targeting the miR- 
145/ZEB2 axis could facilitate 
high glucose (HG) induced 
fibrosis. 
[103] 








Silencing of PVT1 by targeting 
miR-93-5p via PI3K/Akt/mTOR 
pathway could inhibit fibrosis of 
HG-induced mouse mesangial 
cells. 
[122] 
DN Dlx6os1 – MMCs Fibronectin, Coll-I – Inhibition of Dlx6os1 could 
decrease cell proliferation and 
fibrosis in DN. 
[123] 
DN LINC00968 C57BL/KsJ-db/db mice Mesangial EZH2 p21 Silencing of LINC00968 via 
EZH2/p21 axis could inhibit the 
ECM proteins secretion and 
proliferation in mesangial cells. 
[104] 
DN Blnc1 SD rat/ human; 30 pairs of 
serum samples from DN 






NF-kB Blnc1 via NRF2/HO-1 and NF-kB 
pathways could attenuate renal 
fibrosis. 
[124] 




– Metformin by regulating the 
H19/miR-143-3p/TGF-b1 axis 
could inhibit ECM accumulation 
of mesangial cells in DN. 
[122] 
DN Arid2-IR Male C57BL/6 J mice Mesangial Col1A1, α-SMA, – Early growth response protein 1 
(Egr1) by upregulating Arid2-IR 
could promote ECM production 
in diabetic kidney disease. 
[125] 
DN CYP4B1-PS1-001 C57BL/KsJ-db/db mice Mesangial, 
293 T, HK-2 
Fibronectin, Coll-I – CYP4B1-PS1-001 could regulate 
proliferation and fibrosis in DN. 
[126] 




– TGU1 via mediating miR-377/ 
PPARγ axis could alleviate ECM 
accumulation in DN. 
[127] 
DN ZEB1-AS1 db/db mice/human; The 
DN renal tissues from 26 
DN patients and normal 
tissues from 10 patients 
with kidney carcinoma 
without diabetes 
HK-2 miR-217, MAFB, 
Coll-I/IV, α-SMA 
– ZEB1-AS1 by regulating the miR- 
217/MAFB axis could inhibit 
renal fibrosis in DN. 
[128] 
DN CASC2 Serum samples from 2 DN 





– CASC2 via miR-133b/FOXP1 
axis could regulate high glucose- 
induced proliferation and ECM 







intervertebral disc (IVD, 
n = 5) tissues and 
degenerative IVD (n = 30) 
samples 
NP Col-II, MMP-3/13, 
Coll-IV, 
Fibronectin 
Notch1 Overexpression of FAM83H-AS1 
by targeting Notch1 could induce 
nucleus pulposus cell growth and 
modulate ECM expression. 
[130] 
IDD TUG1 10 degenerative tissues and 
10 control NP tissues 




TUG1 via modulating miR-26a/ 
HMGB1 axis and regulating NF- 
kB activation could promote 
ECM degradation in IDD patients. 
[131] 
IDD HOTAIR Male SD rat/human; IVD 
tissue samples from 
patients with lumbar disc 
herniation (n = 30) and 




HOTAIR via regulating the 
AMPK/mTOR/ULK1 pathway 
could stimulate ECM catabolism. 
[132] 
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Table 4 (continued ) 
Cancer type lncRNA Animal/human; Numbers 









(n = 10) 
IDD RP11-296A18.3 36 degenerative tissues and 
30 control NP tissues 
NP MMP-13, Coll-I, 
miR-138, HIF1A 
– RP11-296A18.3 via the miR- 
138/HIF1A axis could regulate 
the proliferation ECM synthesis 
of NP cells. 
[133] 
IDD NEAT1 10 degenerative tissues and 







NEAT1 could contribute to ECM 
degradation in degenerative 
human NP cells. 
[134] 
Keloid H19 keloid tissues (n = 80), 
normal skin tissues 
(n = 91), normal fibrous 






– H19/miR-29a axis through 
acting upon COL1A1 could affect 
the viability and apoptosis of 
keloid fibroblasts. 
[135] 
Keloid ATB Keloid tissues and paired 
normal skin tissue samples 
from 57 patients 
Fibroblast TGF-β2, miR- 
200c, ZNF217 
– Knockdown of ATB by targeting 
ZNF217 via miR-200c could 
suppress the autocrine secretion 
of TGF-β2 in keloid fibroblasts 
[136] 
Skin Fibrosis GAS5 C57BL/6 J mice NIH-3T3, 
fibroblast 
Col1A, α-SMA SMAD-3 GAS5 via inhibiting the SMAD-3 
pathway could attenuate 
fibroblast activation. 
[137] 





Silencing of HOTAIR by 
upregulating miR-124 and 
blocking Notch1 could alleviate 
renal interstitial fibrosis. 
[138] 
RF ENST00000453774.1 C57BL/6 J mice/ human; 
28 pairs of RF and adjacent 
normal control tissues 
HK-2 NQO-1 HO-1 Nrf2- 
keap1 
LncRNA 74.1 downregulated in 
the TGF-β1 (5 ng/mL)-induced 
HK-2 cells. Overexpression of 
lncRNA 74.1 via the Nrf2 axis 
could ameliorate renal fibrosis 
and relieve ECM. 
[139] 
RF ZEB1-AS1 db/db and WT mice/ 
human; kidney biopsy 
samples from patients with 
DN (n = 8) and minimal 




p53 ZEB1-AS1 via p53 could 
associate with renal fibrosis in 
human DN. 
[140] 
Thermal Injury XIST Patients with deep partial- 
thickness burn (n = 25) 
and normal skin tissues 
(n = 25) 
HSF miR-29b-3p, 
COL1A1, α-SMA 
– XIST by targeting miR-29b-3p/ 
COL1A1 could promote ECM 
synthesis and proliferation in 





MALAT1 Male C57BL/6 J mice 
/human; renal fibrotic 
tissues from patients with 
obstructive nephropathy 
(ON, n = 20) and patients 
without NO (n = 20) 
HK-2 miR-145, FAK, E- 
cadherin, α-SMA, 
ZO1, N-cadherin 
– m6A-induced MALAT1 via the 
miR-145/FAK pathway could 





Gm5091 Male C57BL/6 J mice HSC α-SMA, Coll-I, 
miR-27b/23b/24 
– Gm5091 by sponging miR-27b/ 
23b/24 could alleviate ALD in 
mice. 
[143] 
Hepatic Fibrosis GAS5 SD rat HSCs PTEN, miR-23a, E- 
cadherin, α-SMA, 
Coll-I 
PI3K/Akt GAS5 by targeting miR-23a via 
the PTEN/PI3K/Akt pathway 
could restrain CCl4-induced 
hepatic fibrosis. 
[144] 
Hepatic Fibrosis ANRIL SD rat HSC-T6 Col1A1, α-SMA, 
DNMT3A 
– Silencing of ANRIL via activating 
the AMPK pathway could 
enhance liver fibrosis. 
[145] 
Hepatic Fibrosis ATB 18 HCV-infected patients 
with liver fibrosis and 6 
matched healthy subjects 
HSCs, LX-2 Col1A1, miR- 
200a, α-SMA, 
β-catenin ATB via the miR-200a/β-catenin 
could contribute to the 






PFAL C57BL/6 mice Fibroblast CTGF, miR-18a, 
Col1A1, Col3A1 
– PFAL by regulating the miR-18a 
could be involved in pulmonary 
fibrosis. 
[147] 
IPF PFAR Male C57BL/6 mice Fibroblast miR-15a, α-SMA, 
Coll-I/III 
– Silencing of PFAR by targeting 
miR-15a could attenuate TGF-β1 
induced fibrogenesis in primary 
lung fibroblasts. 
[148] 
IPF H19 Male C57BL/6 mice MRC-5, 293 T miR-196a, 
COL1A1, α-SMA 
– H19 by regulating the miR-196a/ 
COL1A1 axis could mediate 
pulmonary fibrosis. 
[149] 





PFAR by targeting miR-138 to 
regulate the YAP1-Twist axis 
could promote lung fibroblast 
activation and fibrosis. 
[150] 
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1.14. ECM-associated lncRNAs and cancer 
ECM constructs a physical hurdle whose incapacitation is an 
important event during cancer progression. A number of lncRNAs 
contribute in this process through destruction of the basal lamina and 
facilitating release of metastatic cells into blood or lymphatic vessels 
[107]. In addition, certain splice variants of lncRNAs may be involved in 
the pathogenesis of specific types of human malignancies. Expression of 
a novel isoform of HOTAIR is activated in Claudin-low breast cancer 
cells that are linked with ECM. This is mediated by the binding of BRD4 
with a novel HOTAIR-N promoter. Activation of HOTAIR expression is 
necessary for the invasive growth of Claudin-low breast cancer cells in 
laminin-rich ECM-based three-dimensional cultures [106,108]. 
Table 4 shows the list of ECM-related lncRNAs and their function in 
human/ animal disorders. 
1.15. ECM-associated lncRNAs and cancer 
ECM constructs a physical hurdle whose incapacitation is an 
important event during cancer progression. A number of lncRNAs 
contribute in this process through destruction of the basal lamina and 
facilitating release of metastatic cells into blood or lymphatic vessels 
[107]. In addition, certain splice variants of lncRNAs may be involved in 
the pathogenesis of specific types of human malignancies. Expression of 
a novel isoform of HOTAIR is activated in Claudin-low breast cancer 
cells that are linked with ECM. This is mediated by the binding of BRD4 
with a novel HOTAIR-N promoter. Activation of HOTAIR expression is 
necessary for the invasive growth of Claudin-low breast cancer cells in 
laminin-rich ECM-based three-dimensional cultures [106,108]. Table 5 
shows the role of ECM-associated lncRNAs in cancer. 
2. Discussion 
ECM has a heterogeneous arrangement. Several proteins, glycos-
aminoglycans, proteoglycans and ECM remodeling enzymes contribute 
Table 4 (continued ) 
Cancer type lncRNA Animal/human; Numbers 








IPF ZEB1-AS1 SD rat RLE-6TN miR-141-3p, 
ZEB1, Coll-I, 
Fibronectin-1, 
– ZEB1-AS1 via the ZEB1/miR- 





H19 Lung samples from PF 
patients (n = 15) and 
normal lung (n = 15) 




Knockdown of H19 by regulating 
miR-140 via the TGF-β/Smad3 
pathway could suppress the 
progress of pulmonary fibrosis. 
[152] 







Smad3 CHRF via miR-489/MyD88/ 
Smad3 axis could inhibit silica- 
induced pulmonary fibrosis. 
[153] 




β-catenin XIST via miR-139/β-catenin axis 
could regulate bleomycin- 





AC067945.2 15 HS tissues and their 




VEGF, Wnt Overexpression of AC067945.2 
via VEGF and Wnt pathways 
could downregulate collagen 





MIAT 69 patients with HCM 
including a fibrosis (+) 
group (N = 30) and a 
fibrosis (− ) group (N = 39) 
A-204, H9C2 miR-29a-3p – MIAT by mediating the 
expression of miR-29a-3p could 





n379599, n342359 15 pairs of cardiac samples 
from patients with ICM and 
controls 
– PAI-1, Snai1, 
Snai2 
TGF-β lncRNAs could be associated 





ENST00000531202.1 Articular cartilage samples 
from KBD patients (n = 5) 





– LncRNAs could be associated 





TCONS_00015374 Articular cartilage samples 
from KBD patients (n = 5) 





– LncRNAs could be associated 





PVT1 C57BL/6 J mice/ human: 
AAA patients (n = 20) and 
control subjects (n = 20) 
VSMC MMP-2, MMP-9, 
TIMP-1 
– Knockdown of PVT1 could 
inhibit ECM disruption in a 





PVT1 C57BL/6 J mice/ human; 
sinus rhythm (SR) group 
(n = 20) and AF group 
(n = 30) 




PVT1 via miR-128-3p/SP1/TGF- 
β1/Smad axis could regulate 
atrial fibrosis in AF. 
[158]  
Table 5 















BRD4 Induction of a 
novel isoform of 
HOTAIR by 
attaching to ECM 
could be involved 
in invasive growth 
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in the construction of ECM. Notably, the composition of ECM and the 
related chemical modifications depend on the natute of tissue of origin 
[160]. Meanwhile, ncRNAs have specific signature in each tissue or 
physiopathological condition. Therefore, these transcripts might be 
involved in the tissue-/condition-specific modifications of ECM. 
NcRNAs contribute to several processes leading to the deposition of ECM 
components and the regulation of cell apoptosis/ survival in tissue mi-
croenvironments. Thus, ncRNAs are considered to contribute to the 
pathogenesis of diverse disorders ranging from cancer to degenerative 
disorders such as OA and IDD and fibrotic pathologies. In malignant 
conditions, ncRNAs regulate the activation of CAFs, which is an 
important process leading to tumor progression. Moreover, alternative 
ECM proteins that are originated from CAFs prompt ECM transformation 
and cancer cell invasion [92]. NF-kB, MAPK, STAT, AKT, TGF-β, and 
Notch pathways are among signaling cascades that are involved in the 
modulation of ECM by ncRNAs. Several growth factors and their re-
ceptors are also implicated in the modulation of ECM proteins by 
ncRNAs. 
The role of lncRNAs in the modulation of ECM is exerted via the 
regulation of several targets, including miRNAs. Some examples of these 
lncRNA/ miRNA axes are RP11-820/ miR-3178, PFAR/ miR-15a, Gas5/ 
miR-23a, Gm5091/ miR-27b/23b/24, CASC2/ miR-133b, TUG1/ miR- 
377 and MIAT/ miR-29a-3p. Thus, the interaction between lncRNAs 
and miRNAs has a pivotal role in the modulation of ECM. Based on the 
extensive functions of ncRNAs in the pathogenesis of ECM-related dis-
orders, these transcripts are regarded as promising therapeutic targets in 
a vast spectrum of human disorders. Although the extent to which 
lncRNAs can affect miRNAs is unclear, identification of lncRNA-miRNA 
competing endogenous networks is an important consideration for the 
selection of best therapeutic targets and implementation of targeted 
therapies. Some lncRNA/ miRNA axes have been successfully targetted 
for the treatment of ECM-related conditions. For instance, H19/miR-29a 
axis has been targeted for the treatment of keloids. Expression assays 
displayed over-expression of H19 while down-regulation of miR-29a in 
keloid tissues and fibroblasts compared with normal skin tissues and 
fibroblasts. H19 knockdown and miR-29a overexpression could inhibit 
metastasis and proliferation of fibroblasts [135]. Several animal studies 
have shown the efficacy of lncRNA or miRNA-targeted therapies in 
ECM-related pathological conditions. For instance, siRNA-mediated 
silencing of XIST has been shown to be effective in the prevention of 
OA in rat models [102]. Moreover, miR-101 silencing can inhibit 
cartilage destruction in a rat model of OA through modulation of ECM 
related genes [60]. However, the translation of these basic data into 
clinical application is a complicated process due to the presence of 
several safety and bioavailability concerns. 
NcRNAs are effectively involved in the dynamics of ECM which in 
turn controls initiation, expansion and metastaisis of tumors. It is worth 
mentioning that idenification of the role of ncRNAs in the modification 
of ECM needs precise isolation of different cell populations and assess-
ment of expression of these transcripts in each cell population in 
different pathological conditions. The role of ncRNAs in the modulation 
of tumor-stroma interaction is also exerted through relaese of cell-free 
particles such as exosomes. Therefore, assessment of expression of 
these transcripts in the exosomes is another approach that facilitates 
identification of the role of ncRNAs in this regard. 
NcRNAs are also involved in the molecular mechanisms leading to 
the efficacy of prescribed medications for ECM-associated pathologies. 
For instance, metformin is an effective drug prescribed for diabetic ne-
phropathy and has been shown to suppress ECM deposition, inflam-
matory responses, and proliferation of mesangial cells through 
modulation of the H19/miR-143-3p/TGF-β1 pathway [122]. 
Finally, ncRNAs can serve as diagnostic and prognostic markers in 
ECM-related pathologies. Notably, a number of lncRNAs and miRNAs 
that work together can be exploited to enhance diagnostic or prognostic 
accuracy. For instance, both MIAT and miR-29a have been shown to 
predict the prognosis of patients with hypertrophic cardiomyopathy 
[102]; thus, the combination of these markers might enhance the 
prognostic value. The prognostic role of a number of ECM-associated 
miRNAs has been evaluated in cancer patients. However, the diag-
nostic/ prognostic values of other ECM-associated ncRNAs have not 
been evaluated in other conditions. Thus, a potentially important future 
direction for research would be in the identification of ncRNA markers, 
particularly in peripheral blood or serum samples of patients to allow a 
non-invasive diagnosis of ECM-related pathologies. 
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